Package Leaflet: Information for the Patient
Clefirem 14 mgfilm-coated tablets
teriflunomide
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack
Clefirem contains the active substance teriflunomide, which is an immunomodulatory agent that adjusts the immune system to limit its attack on the nervous system.
What Clefirem is used for
Teriflunomide is used in adults and in children and adolescents (10 years of age and older, weighing over 40 kg) to treat relapsing-remitting multiple sclerosis (MS).
What is multiple sclerosis
MS is a long-term disease that affects the central nervous system (CNS). The CNS is made up of the brain and spinal cord. In multiple sclerosis, inflammation destroys the protective sheath (myelin) that surrounds the nerves of the CNS. This loss of myelin is called demyelination. This makes the nerves stop working properly.
People with the relapsing form of multiple sclerosis will have repeated attacks (relapses) of physical symptoms caused by the poor functioning of the nerves. These symptoms vary from person to person but usually include:
The symptoms can disappear completely after a relapse, but over time, some problems may remain. This can cause physical disabilities that can interfere with daily activities.
How Clefirem works
Teriflunomide helps protect against attacks on the central nervous system by the immune system, limiting the growth of some white blood cells (lymphocytes). This limits the inflammation that causes nerve damage in MS.
Do not takeClefirem
In case of doubt, ask your doctor or pharmacist before taking this medicine.
Warnings and precautions
Tell your doctor or pharmacist before starting teriflunomide if:
Respiratory reactions
Tell your doctor if you have unexplained cough and shortness of breath. Your doctor may perform additional tests.
Children and adolescents
Teriflunomide is not indicated for use in children under 10 years of age, as it has not been studied in patients with MS in this age group.
The warnings and precautions listed above also apply to children. The following information is important for children and their caregivers:
Other medicines and Clefirem
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines. This includes medicines without a prescription.
In particular, tell your doctor or pharmacist if you are taking any of the following medicines:
Pregnancy and breast-feeding
Do not take teriflunomide if you are pregnant or think you may be pregnant. If you are pregnant or become pregnant while taking teriflunomide, there is an increased risk of having a baby with birth defects. Women of childbearing age must not take this medicine if they are not using reliable contraceptive methods.
If your daughter has her first period while taking teriflunomide, she must inform her doctor, who will provide specialized advice on contraceptive methods and potential risks in case of pregnancy.
Tell your doctor if you plan to become pregnant after stopping treatment with this medicine, as you need to make sure that most of the medicine has been eliminated from your body before trying to become pregnant. The natural elimination of the active substance may take up to 2 years. This period can be reduced to a few weeks by taking certain medicines to accelerate the elimination of teriflunomide from the body. In any case, you need your doctor to confirm, based on a blood test, that the level of active substance in your blood is low enough for you to become pregnant.
For more information on laboratory tests, contact your doctor.
If you suspect you are pregnant while taking teriflunomide or in the 2 years following treatment, you must stop taking teriflunomide and contact your doctor immediately for a pregnancy test. If the test confirms pregnancy, your doctor may suggest treatment with certain medicines to eliminate teriflunomide from your body quickly, as this may reduce the risk to your baby.
Contraception
You must use an effective contraceptive method during and after treatment with this medicine. Teriflunomide remains in the blood for a long time after stopping treatment. Continue to take contraceptive measures after stopping treatment.
Do not take this medicine during breast-feeding, as teriflunomide passes into breast milk.
Driving and using machines
Teriflunomide may cause dizziness, which may affect your ability to concentrate and react. If you are affected, do not drive or use machines.
Clefirem contains lactose
This medicine contains lactose (a type of sugar). If your doctor has told you that you have an intolerance to some sugars, consult them before taking this medicine.
Clefirem contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per tablet; this is essentially "sodium-free".
A doctor with experience in treating multiple sclerosis will supervise treatment with teriflunomide.
Follow the instructions for administration of this medicine exactly as prescribed by your doctor. If you are unsure, consult your doctor again.
Adults, children, and adolescents (10 years of age and older, weighing over 40 kg)
The recommended dose is one 14 mg tablet per day.
Form/Route of Administration
Teriflunomide is administered orally. This medicine is taken once daily, at any time of day.
Swallow the tablet whole with a little water. Do not break, crush, or chew the tablet before swallowing, as this may change the amount of medicine that enters your body.
Teriflunomide can be taken with or without food.
If you take more Clefiremthan you should
If you have taken too much teriflunomide, call your doctor immediately. You may experience side effects similar to those described in section 4 (below).
If you forget to take Clefirem
Do not take a double dose to make up for forgotten doses. Take your next dose at the scheduled time.
If you stop taking Clefirem
Do not stop treatment or change the dose of this medicine without consulting your doctor first. If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Serious side effects
Some side effects may be serious, if you experience any of these, tell your doctor immediately.
Common(may affect up to 1 in 10 people)
Uncommon(may affect up to 1 in 100 people)
Frequency not known(frequency cannot be estimated from the available data):
Other side effectsmay occur with the following frequencies:
Very common(may affect more than 1 in 10 people)
Common(may affect up to 1 in 10 people)
Uncommon(may affect up to 1 in 100 people)
Rare(may affect up to 1 in 1,000 patients)
Frequency not known(frequency cannot be estimated with the available data)
Children (10 years of age and older) and adolescents
The side effects listed above also apply to children and adolescents. The following additional information is important for children, adolescents, and their caregivers:
Common(may affect up to 1 in 10 people)
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton after "EXP". The expiry date refers to the last day of the month shown.
This medicine does not require any special storage conditions.
Medicines should not be disposed of via wastewater or household waste. Return any unused medicine to your pharmacist. In case of doubt, ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Composition ofClefirem
The active ingredient is teriflunomide.
Clefirem 14 mg film-coated tablets EFG
Appearance of the Product and Packaging Content
Clefirem 14 mg film-coated tablet EFG (tablets)
Clefirem is a film-coated tablet of pale blue color, round, approximately 7.1 mm in diameter, biconvex and smooth on both sides.
Clefirem 14 mg film-coated tablets EFG are presented in aluminum blisters in boxes of 28 or 84 film-coated tablets.
Only some pack sizes may be marketed.
Marketing Authorization Holder
Bausch Health Ireland Limited
Lake Drive 3013
Citywest Business Campus
Dublin 24 D24PPT3
Ireland
Manufacturer
Bausch Health Poland Sp. z.o.o.
Ul. Przemyslowa 2
35-959 Rzeszów
Poland
Bausch Health Poland Sp. z.o.o.
Ul. Kosztowska 21
41-409 Myslowice
Poland
Date of the Last Revision of this Leaflet: September 2024
Detailed information on this medicinal product is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) (http://www.aemps.gob.es/